A Phase 3 interventional study of Tenecteplase in Dysfunctional Hemodialysis Catheters, sponsored by Genentech, Inc.. Completed. Per ClinicalTrials.gov, last updated 2017-01-12.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.
The study consisted of four visits that corresponded to consecutive HD sessions for each patient, as well as one follow-up visit. Patients could receive up to three treatments with open-label tenecteplase during the study: one or two treatments during an initial treatment course, and eligible patients whose catheter became dysfunctional again within 21 days of the first visit received an additional treatment as part of a retreatment (RT) course.
At Visit 1, patients eligible at the beginning of HD had 2 mL (2 mg) of tenecteplase instilled into each of the two lumens of the HD catheter. After a dwell time of 1 hour, study drug was withdrawn and all subjects underwent HD. The duration of the HD session was not fixed by the study protocol, but rather by the site's HD practice, physician orders, and individual patient response during the session. Patients who did not experience treatment success at the end of Visit 1 had 2 mL (2 mg) of tenecteplase instilled into each lumen of their catheter as part of the initial treatment course. The treatment was left to dwell for an extended time, until the second HD session at Visit 2 (up to 72 hours later). Patients who received extended-dwell tenecteplase had the treatment withdrawn from their catheter at the beginning of Visit 2. Patients underwent HD as prescribed or to the extent possible.
Patients who had treatment success at Visit 1 or Visit 2 and had a recurrence of catheter dysfunction within 21 days of Visit 1 and met the re-treatment eligibility criteria had 2 mL (2 mg) of tenecteplase instilled into each lumen, followed by a 1-hour dwell time at re-treatment Visit 1.
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: for the Study
Exclusion Criteria: for the Study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
Drug: Tenecteplase
2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1
Treatment success is defined as Blood Flow Rate (BFR) ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of hemodialysis and at the end of hemodialysis.
Time frame: Visit 1 (the first hemodialysis session in which treatment was administered). BFR was measured at the beginning of hemodialysis (Baseline measurement) and at 30 minutes prior to the end of hemodialysis and at the end of hemodialysis.
Targeted Adverse Events From the Initial Study Drug Administration Through the Start of Visit 2 or Until Instillation of Extended-Dwell Tenecteplase
The primary outcome measure was the number of targeted adverse events, occurring from initial study drug administration through the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for subjects who did not receive open-label, extended-dwell tenecteplase, from initial study administration through the start of Visit 2. Targeted adverse events were defined as intracranial hemorrhage, major bleeding and embolic events, thrombosis, Catheter-related blood stream infection (CRBSIs), and catheter-related complications.
Time frame: From initial study drug administration to the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for patients who did not receive extended-dwell tenecteplase, from initial study administration to the start of Visit 2.
Percentage of Participants Who Maintained Catheter Function at Visits 2 and 3
For patients with treatment success at Visit 1 or Visit 2, maintenance of catheter function at subsequent visits was defined as a BFR ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated target arterial pressure in the range of 0 to -280 mmHg at the beginning of that HD session (within the first 30 minutes).
Time frame: Maintenance BFR measurements were taken at the beginning of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) and Visit 3 (3rd consecutive HD session, within 72 hours of Visit 2).
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 1
The urea reduction ratio (URR) was calculated from measurements of blood urea nitrogen (BUN) as follows: (Pre-treatment BUN) - (Post-HD BUN) \* 100% / (Pre-treatment BUN) Pre-treatment URR was assessed within 30-60 minutes after the initiation of HD and does not represent a true baseline value.
Time frame: At Visit 1 (first hemodialysis session in which treatment was administered) samples for blood urea nitrogen measurements were taken at the beginning of HD (prior to treatment administration) and after HD was completed.
Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 2
The urea reduction ratio (URR) at Visit 2 was calculated for those participants who did not receive extended-dwell tenecteplase at Visit 1 from measurements of blood urea nitrogen (BUN) as follows: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)
Time frame: At Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1) samples for blood urea nitrogen measurements were taken prior to HD and after HD was completed.
Change in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 1
Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 1 - BFR at Baseline.
Time frame: Baseline (beginning of HD at Visit 1) to the end of HD at Visit 1.
Percentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 2
Patients who failed treatment at Visit 1 and were treated with extended-dwell tenecteplase were analyzed for Treatment Success at Visit 2. Treatment success at Visit 2 was defined as a BFR ≥ 300 mL/min, without line reversal, and increase of ≥ 25 mL/min from baseline BFR, at an associated target arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of HD and at the end of HD.
Time frame: BFR was measured 30 minutes before the end of HD and at the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1). Baseline BFR was measured at the beginning of HD at Visit 1.
Percentage of Participants Who Failed Treatment at Visit 1 With a Urea Reduction Ratio ≥ 65% at Visits 2 and 3
Patients who experienced treatment failure at the end of Visit 1 and were eligible for and treated with extended-dwell tenecteplase at Visit 1 were assessed for Urea Reduction Ratio (URR) at Visits 2 and 3. URR was calculated from blood urea nitrogen (BUN) measurements according to the following: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)
Time frame: Blood urea nitrogen measurements were taken prior to HD and at the end of HD at Visits 2 (2nd HD session, within 72 hours after visit 1) and 3 (3rd HD session, within 72 hours of Visit 2)
Change in Blood Flow Rate From Baseline to the End of HD at Visit 2
Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 2 - BFR at Baseline.
Time frame: Baseline (beginning of HD at Visit 1) to the end of HD at Visit 2 (2nd consecutive HD session, within 72 hours of Visit 1).
| Milestone | Tenecteplase |
|---|---|
| Started | 223 |
| Completed | 210 |
| Not completed | 13 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Death | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Change in eligibility status | 1 |
Treatment success is defined as Blood Flow Rate (BFR) ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of hemodialysis and at the end of hemodialysis.
| Percentage of participants | Tenecteplase |
|---|---|
| Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 | 34.1 |
The primary outcome measure was the number of targeted adverse events, occurring from initial study drug administration through the end of Visit 1 (prior to administration of open-label, extended-dwell tenecteplase) or, for subjects who did not receive open-label, extended-dwell tenecteplase, from initial study administration through the start of Visit 2. Targeted adverse events were defined as intracranial hemorrhage, major bleeding and embolic events, thrombosis, Catheter-related blood stream infection (CRBSIs), and catheter-related complications.
| Events | Tenecteplase |
|---|---|
| Intracranial hemorrhage | 0 |
| Major bleeding | 0 |
| Embolic event | 0 |
| Thrombosis | 1 |
| Catheter-related blood stream infection | 2 |
| Catheter-related complication | 0 |
For patients with treatment success at Visit 1 or Visit 2, maintenance of catheter function at subsequent visits was defined as a BFR ≥ 300 mL/min and an increase of ≥ 25 mL/min from baseline BFR (without reversal of lines), at an associated target arterial pressure in the range of 0 to -280 mmHg at the beginning of that HD session (within the first 30 minutes).
| percentage of participants | Tenecteplase |
|---|---|
| Visit 2 (n=72) | 69.4 (58.8 to 80.1) |
| Visit 3 (n=71) | 62.0 (50.7 to 73.3) |
The urea reduction ratio (URR) was calculated from measurements of blood urea nitrogen (BUN) as follows: (Pre-treatment BUN) - (Post-HD BUN) \* 100% / (Pre-treatment BUN) Pre-treatment URR was assessed within 30-60 minutes after the initiation of HD and does not represent a true baseline value.
| percentage of participants | Tenecteplase |
|---|---|
| Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 1 | 23.8 (18.2 to 29.4) |
The urea reduction ratio (URR) at Visit 2 was calculated for those participants who did not receive extended-dwell tenecteplase at Visit 1 from measurements of blood urea nitrogen (BUN) as follows: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)
| percentage of participants | Tenecteplase |
|---|---|
| Percentage of Participants With Urea Reduction Ratio ≥ 65% at Visit 2 | 34.6 (25.6 to 43.6) |
Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 1 - BFR at Baseline.
| mL/min | Tenecteplase |
|---|---|
| Change in Blood Flow Rate From Baseline to the End of Hemodialysis at Visit 1 | 81.9 ± 123.84 |
Patients who failed treatment at Visit 1 and were treated with extended-dwell tenecteplase were analyzed for Treatment Success at Visit 2. Treatment success at Visit 2 was defined as a BFR ≥ 300 mL/min, without line reversal, and increase of ≥ 25 mL/min from baseline BFR, at an associated target arterial pressure in the range of 0 to -280 mmHg, 30 (± 10) minutes prior to the end of HD and at the end of HD.
| percentage of participants | Tenecteplase |
|---|---|
| Percentage of Participants Who Failed Treatment at Visit 1 With Treatment Success at Visit 2 | 49.1 (40.0 to 58.2) |
Patients who experienced treatment failure at the end of Visit 1 and were eligible for and treated with extended-dwell tenecteplase at Visit 1 were assessed for Urea Reduction Ratio (URR) at Visits 2 and 3. URR was calculated from blood urea nitrogen (BUN) measurements according to the following: (Pre-HD BUN) - (Post-HD BUN) \* 100% / (Pre-HD BUN)
| percentage of participants | Tenecteplase |
|---|---|
| URR ≥ 65% at Visit 2 | 42.2 (33.3 to 51.2) |
| URR ≥ 65% at Visit 3 | 33.6 (25.0 to 42.2) |
Change in Blood flow rate (BFR) is the BFR at the end of HD for Visit 2 - BFR at Baseline.
| mL/minute | Tenecteplase |
|---|---|
| Change in Blood Flow Rate From Baseline to the End of HD at Visit 2 | 117.1 ± 139.96 |
Collected over Begins at initiation of study treatment and ends upon completion of the second visit following the last administration of study treatment or at early termination from the study, whichever is earlier.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenecteplase | — | 9/223 (4%) | 36/223 (16.1%) |
| Event | Tenecteplase |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/223 |
| PainGeneral disorders | 1/223 |
| BacteraemiaInfections and infestations | 1/223 |
| Catheter BacteraemiaInfections and infestations | 1/223 |
| GangreneInfections and infestations | 1/223 |
| Infected Skin UlcerInfections and infestations | 1/223 |
| SepsisInfections and infestations | 1/223 |
| Staphylococcal BacteraemiaInfections and infestations | 1/223 |
| Procedural PainInjury, poisoning and procedural complications | 1/223 |
| HypertensionVascular disorders | 1/223 |
| Event | Tenecteplase |
|---|---|
| NauseaGastrointestinal disorders | 4/223 |
| HeadacheNervous system disorders | 4/223 |
| HypotensionVascular disorders | 3/223 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 2/223 |
| PruritusSkin and subcutaneous tissue disorders | 2/223 |
| HypertensionVascular disorders | 2/223 |
| Haemodynamic InstabilityVascular disorders | 2/223 |
| ConstipationGastrointestinal disorders | 1/223 |
| DiarrhoeaGastrointestinal disorders | 1/223 |
| DyspepsiaGastrointestinal disorders | 1/223 |
| Age, Customized(participants) | Tenecteplase |
|---|---|
| < 17 years | 1 |
| >= 17 years to < 65 years | 120 |
| >= 65 years | 102 |
| Age, Continuous(years) | Tenecteplase |
|---|---|
| Mean | 61.2 ± 16.3 |
| Gender(Participants) | Tenecteplase |
|---|---|
| Female | 124 |
| Male | 99 |
No study locations are listed for this record.
The record gives a start of Nov 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 2 years 10 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase